Jun 05, 2024 4:01 pm EDT Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024 4:01 pm EDT Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 20, 2024 9:25 am EDT Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 09, 2024 4:01 pm EDT Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 03, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 05, 2024 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 28, 2024 8:30 am EDT Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Feb 29, 2024 9:05 am EST Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Feb 28, 2024 4:30 pm EST Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Feb 14, 2024 9:00 am EST Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis